Lipopolysaccharides in the development of the Guillain-Barré syndrome and Miller Fisher syndrome forms of acute inflammatory peripheral neuropathies

Journal of Endotoxin Research

Volumn 6, Issue 5, 2000, Pages 341-359

  Prendergast, M M ^a   Moran, A P ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD 1A; GANGLIOSIDE GD2; GANGLIOSIDE GD3; GANGLIOSIDE GM1; GANGLIOSIDE GM2; IMMUNOGLOBULIN; METHYLPREDNISOLONE;

ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIGEN PRESENTATION; CAMPYLOBACTER JEJUNI; CARBOHYDRATE ANALYSIS; CHEMISTRY; DISEASE CLASSIFICATION; ENTERITIS; GASTROENTERITIS; GUILLAIN BARRE SYNDROME; HOST; HUMAN; IMMUNOTHERAPY; INFECTION; INFLAMMATION; INFORMATION PROCESSING; MEDICAL RESEARCH; MOLECULAR MIMICRY; NONHUMAN; PATHOGENESIS; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; POLYNEUROPATHY; REVIEW; SEROTYPE; SEROTYPING; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, BACTERIAL; CAMPYLOBACTER INFECTIONS; CAMPYLOBACTER JEJUNI; CARBOHYDRATE SEQUENCE; CROSS REACTIONS; GANGLIOSIDES; GUILLAIN-BARRE SYNDROME; HUMANS; LIPOPOLYSACCHARIDES; MILLER FISHER SYNDROME; MODELS, BIOLOGICAL; MOLECULAR MIMICRY; MOLECULAR SEQUENCE DATA; SEROTYPING; T-LYMPHOCYTES;

ACRONICTA LEPORINA; ANIMALIA; BACTERIA (MICROORGANISMS); CAMPYLOBACTER JEJUNI; MARTES PENNANTI;

EID: 0034461347     PISSN: 09680519     EISSN: None     Source Type: Journal    
DOI: 10.1179/096805100101532270     Document Type: Review

References (222)

1. Assessment of current diagnostic criteria for Guillain-Barré syndrome
2. Sur un syndrome de radiculoneurite avec hyperalbuminose du liquide cephalo-rachidien sans reaction cellulaire
3. Pathogenesis of Guillain-Barré syndrome
4. Guillain-Barré syndrome: Its epidemiology and associations with influenza vaccination
5. Acute inflammatory demyelinating polyradiculoneuropathy
6. National surveillance for Guillain-Barré syndrome: January 1978-March 1979
7. Foodborne illness: Campylobacter
8. An outbreak of presumptive food-borne Campylobacter enteritis
9. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies
10. The Guillain-Barré syndrome
11. Campylobacter jejuni infection and Guillain-Barré syndrome
12. Human autoimmune neuropathies
13. Axonal damage in Guillain-Barré syndrome
14. Pathology of the motor-sensory axonal Guillain-Barré syndrome
15. Guillain-Barre syndrome
16. Acute polyradiculitis (Guillain-Barré syndrome): An epidemiological study of 156 cases observed in Beijing
17. Development of Guillain-Barré syndrome following Campylobacter infection
18. Paralytic syndromes associated with noninflammatory cytoplasmic or nuclear neuropathy
19. 1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome
20. Acute idiopathic axonal neuropathy (AIAN): A clinical and electrophysiological observation
21. Guillain-Barré syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases
22. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia)
23. Serum factor in the Miller Fisher variant of Guillain-Barré syndrome blocks neurotransmitter release
24. Brainstem encephalitis and the syndrome of Miller Fisher, a clinical study
25. Plasmapheresis and acute Guillain-Barré syndrome
26. Efficiency of plasma exchange in Guillain-Barré syndrome: Role of replacement fluids
27. A randomized trial comparing intravenous globulin and plasma exchange in Guillain-Barré syndrome
28. Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methyl-prednisolone: A pilot study
29. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome
30. Controlled trial of prednisone in acute polyneuropathy
31. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome
32. Immunopathogenesis and treatment of the Guillain-Barré syndrome-Part 1
33. Gangliosides: Structure, isolation, and analysis
34. Structure and localization of gangliosides
35. GM1 ganglioside treatment of Parkinson's disease: An open pilot study of safety and efficacy
36. Acute axonal Guillain-Barré syndrome with IgG antibody against motor axons following parenteral gangliosides
37. Motor neuropathies, motor neuron disorders, and anti-glycolipid antibodies
38. Serum antibodies to gangliosides in Guillain-Barré syndrome
39. Antibody detection in Guillain-Barré syndrome
40. 1 antibodies following Campylobacter enteritis
41. 1 ganglioside
42. In vivo effect of sera from patients with Guillain-Barré subgroups: An electrophysiological and histological study on rat nerves
43. Association between glycoconjugate antibodies and Campylobacter infection in patients with Guillain-Barré syndrome
44. 1 antibodies in patients with Guillain-Barré syndrome
45. The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders
46. 1 antibodies in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy
47. lb ganglioside
48. 1 antibodies in Guillain-Barré syndrome: Isotypes, course and clinical outcome
49. Seroreactivity to Campylobacter jejuni and gangliosides in patients with Guillain-Barré syndrome
50. 1 IgG antibodies and Campylobacter bacteria in Guillain-Barré syndrome: Evidence of molecular mimicry
51. 1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection
52. 1 antibodies in Guillain-Barré syndrome
53. Autoantibodies to peripheral nerve glycosphingolipids SPG, SPLG, and SGPG in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy
54. Electrophysiological classification of Guillain-Barré syndrome: Clinical associations and outcome
55. Close association of IgA anti-ganglioside antibodies with antecedent Campylobacter jejuni in Guillain-Barré syndrome
56. Antibodies to gangliosides and galactocerebroside in patients with Guillain-Barré syndrome with preceding Campylobacter jejuni infection and other identified infections
57. la antibody-associated Guillain-Barré syndrome with a predominantly distal weakness without cranial nerve impairment and sensory disturbance
58. Antiganglioside antibody in patients with Guillain-Barré syndrome who show bulbar palsy as an initial symptom
59. la antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome
60. lb is a new member of antigen for serum antibody in Guillain-Barré syndrome
61. la
62. la: Relationship to Campylobacter jejuni infection and acute motor axonal neuropathy in China
63. 1 IgA antibodies in Guillain-Barré syndrome
64. 1 antibodies
65. Antibodies to gangliosides in Guillain-Barré syndrome: Specificity and relationship to clinical features
66. 1b, peripheral nerve myelin, and Campylobacter jejuni in patients with Guillain-Barré syndrome and controls: Correlation and prognosis
67. 1 ganglioside-like structure
68. 1a is a target molecule for serum antibody in Guillain-Barré syndrome
69. Clinical presentation and outcome of Guillain-Barré and related syndromes in relation to anti-ganglioside antibodies
70. 1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: Clinical and immunohistochemical studies
71. 1b antibody in Fisher's syndrome
72. lb antibody
73. 1b antibodies in Guillain-Barré syndrome
74. 1b antibodies in peripheral neuropathy
75. 1b IgG antibody activities related to severity of Miller Fisher syndrome
76. 1 and sulphatide of peripheral nerve myelin
77. 1, in Guillain-Barre syndrome
78. 1b in Guillain-Barré syndrome subsequent to Campylobacter jejuni enteritis
79. 1a antibodies
80. 1a antibodies
81. 1a ganglioside in patients with Guillain-Barré syndrome
82. Search for antibodies to neutral glycolipids in sera of patients with Guillain-Barré syndrome
83. Localisation of neural epitopes that bind to IgM monoclonal autoantibodies (M-proteins) from two patients with motor neuron disease
84. Ganglioside autoantibodies
85. Antibody crossactivities between gangliosides and lipopolysaccharides of Campylobacter jejuni serotypes associated with Guillain-Barré syndrome
86. lb antibodies in Miller Fisher syndrome
87. 1a gangliosides
88. 1b ganglioside in a pharyngeal-cervical-brachial variant of Guillain-Barré syndrome
89. Campylobacter jejuni and the expanding spectrum of related infections
90. Role of infection due to Campylobacter jejuni in the initiation of Guillain-Barré syndrome
91. Serologic evidence of previous Campylobacter jejuni infection in patients with the Guillain-Barré syndrome
92. 2 antibodies in Guillain-Barré syndrome
93. Anti-ganglioside antibodies in Guillain-Barré syndrome following recent cytomegalovirus infection
94. The spectrum of antecedent infections in Guillain-Barré syndrome: A case-control study
95. Guillain-Barré syndrome associated with Campylobacter infection
96. Guillain-Barré syndrome associated with Campylobacter infection
97. The Guillain-Barré syndrome following Campylobacter enteritis with recovery after plasmapheresis
98. Guillain-Barré syndrome associated with Campylobacter enteritis
99. Guillain-Barré syndrome associated with Campylobacter infection
100. Acute polyneuritis with cranial nerve involvement following Campylobacter jejuni infection
101. Guillain-Barré syndrome associated with Campylobacter enteritis in a child
102. Guillain-Barré syndrome following Campylobacter jejuni enteritis
103. Campylobacter diarrhea and Guillain-Barré syndrome
104. Guillain-Barré syndrome following Campylobacter jejuni enteritis. Report of three cases and review of the literature
105. Neurological disorders in Campylobacter infections. Five cases
106. Another case of atypical acute axonal polyneuropathy following Campylobacter enteritis
107. Guillain-Barré syndrome associated with Campylobacter infection
108. HLA-B35 and acute axonal polyneuropathy following Campylobacter infection
109. Serotype of Campylobacter jejuni, HLA, and the Guillain-Barré syndrome
110. Specific serotype of Campylobacter jejuni associated with Guillain-Barré syndrome
111. Campylobacter jejuni strains from patients with Guillain-Barré syndrome belong mostly to Penner serogroup 19 and contain β-N-acetylglucosamine residues
112. Guillain-Barré syndrome in South Africa associated with Campylobacter jejuni 0:41 strains
113. Mild forms of Guillain-Barré syndrome in an epidemiologic survey in the Netherlands
114. Guillain-Barré syndrome and Campylobacter jejuni: A serological study
115. Campylobacter jejuni/Campylobacter coli-associated Guillain-Barré syndrome. Immunoblot confirmation of the serological response
116. A prospective study of acute idiopathic neuropathy. II. Antecedent events
117. Association between glycoconjugate antibodies and Campylobacter infection in patients with Guillain-Barré syndrome
118. Clinical and serological studies in a series of 45 patients with Guillain-Barré syndrome
119. Seroreactivity to Campylobacter jejuni and gangliosides in patients with Guillain-Barré syndrome
120. Campylobacter jejuni infection and treatment for Guillain-Barré syndrome
121. Campylobacter jejuni isolates from Japanese patients with Guillain-Barré syndrome
122. Serologic evidence of Campylobacter jejuni/coli enteritis in patients with Guillain-Barré syndrome
123. Detection of Campylobacter jejuni Campylobacter coli infection in patients with Guillain-Barré syndrome by serology and culture
124. Campylobacters in the Third World: What do they matter?
125. Campylobacter jejuni
126. Epidemiology of Campylobacter jejuni infections in the US and other industrialized nations
127. Campylobacter enteritis in the United States. A multicenter study
128. Campylobacter enteritis in general practice
129. A demographic survey of Campylobacter, Salmonella and Shigella infections in England. A public Health Laboratory Service Survey
130. Campylobacter enteritidis: Epidemiological and clinical data from recent isolations in the region of Freiburg, West Germany
131. A further study of the epidemiology of Campylobacter jejuni infections
132. Rate of Campylobacter spp. isolation in three regions of Ontario, Canada, from 1978 to 1985
133. Campylobacter jejuni infection in Haifa Subdistrict, Israel, Summer 1981
134. Serotyping of Campylobacter jejuni and Campylobacter coli on the basis of thermostable antigens
135. Serological analysis of the heat-stable antigens involved in serotyping Campylobacter jejuni and Campylobacter coli
136. Serotyping of Campylobacter jejuni based on heat-stable antigens: Relevance, molecular basis and implications in pathogenesis
137. Functional aspects and nature of the lipopolysaccharide receptor of human erythrocytes
138. Structural and antigenic properties of lipopolysaccharide from serotype reference-strains of Campylobacter jejuni
139. Characterization of cross-reacting serotypes of Campylobacter jejuni
140. Structural and antigenic heterogeneity of lipopolysaccharides of Campylobacter jejuni and Campylobacter coli
141. Composition and antigenic activity of the oligosaccharide moiety of Haemophilus influenzae type lipooligosaccharide
142. Antigenic and physical diversity of Neisseria gonorrhoeae lipooligosaccharide
143. Potential role of lipopolysaccharides of Campylobacter jejuni in the development of Guillain-Barré syndrome
144. Chemical structure of the core regions of Campylobacter jejuni serotypes O:1, O:4, O:23, and O:36 lipopolysaccharides
145. The lipooligosaccharides of pathogenic Gram-negative bacteria
146. Heat-stable serotyping antigens expressed by strains of Campylobacter jejuni are probably capsular and not long-chain lipopolysaccharide
147. Genetic and biochemical evidence of a Campylobacter jejuni capsular polysaccharide that accounts for Penner serotype specificity
148. Characterization of the antigens involved in serotyping strains of Campylobacter by passive haemagglutination
149. Chemical structures of the core region of Campylobacter jejuni O:3 lipopolysaccharide and an associated polysaccharide
150. Chemical structure of a polysaccharide from Campylobacter jejuni 176.83 (serotype O:41) containing only furanose sugars
151. Lipooligosaccharide of the Campylobacter lari type strain ATCC 3521. Structure of the liberated oligosaccharide and an associated extracellular polysaccharide
152. Lipooligosaccharide of the Campylobacter lari strain PC637. Structure of the liberated oligosaccharide and an associated extracellular polysaccharide
153. Molecular mimicry of host structures by lipopolysaccharides of Campylobacter and Helicobacter spp.: Implications in pathogenesis
154. Molecular mimicry of host structures by bacterial lipopolysaccharide and its contribution to disease
155. Campylobacter Species and Guillain-Barré syndrome
156. 1b IgG antibodies recognize surface epitopes on Campylobacter jejuni from patients with Miller Fisher syndrome
157. 3
158. Chemical characterization of Campylobacter jejuni lipopolysaccharides containing N-acetylneuraminic acid and 2 ,3-diamino-2,3-dideoxy-D-glucose
159. Chemical structure of the core region of Campylobacter jejuni serotype O:2 lipopolysaccharide
160. Lipopolysaccharides of Campylobacter jejuni serotype O:19. Structures of the core oligosaccharide regions from the serostrain and two bacterial isolates from patients with the Guillain-Barré syndrome
161. 1 and lipopolysaccharide from Penner's serotype 19 of Campylobacter jejuni
162. 1 ganglioside
163. Lipopolysaccharides from a neuropathy-associated infection from Campylobacter jejuni serotype O:23
164. 1-like lipo-oligosaccharide of Campylobacter jejuni
165. Phase variation of Campylobacter jejuni lipooligosaccharide affects virulence
166. Serum antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in Miller Fisher syndrome
167. Ganglioside-induced antiganglioside antibodies from a neuropathy patient cross-react with lipopolysaccharides of Campylobacter jejuni associated with Guillain-Barré syndrome
168. 1 in chronic neuropathies cross react with Campylobacter jejuni lipopolysaccharides
169. 1 ganglioside show diverse cross-reactivity with lipopolysaccharides of Campylobacter jejuni strains associated with Guillain-Barré syndrome
170. 1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome
171. Antibodies to glycoconjugates in neurological disease
172. 1 antibodies cloned from motor neuropathy patients demonstrates diverse variable region gene usage with extensive somatic mutation
173. Campylobacter jejuni lipopolysaccharide in Guillain-Barré syndrome: Molecular mimicry and host susceptibility
174. 1 ganglioside antibodies
175. 1b are antigens for IgM M-protein in a patient with motor neuron disease
176. 1 antibodies, and multifocal motor conduction block
177. 1 and Gal(β1-3) GalNAc antigenic determinants in peripheral nerve
178. The pattern of antiganglioside antibody reactivities producing myelinated nerve conduction block in vitro
179. + currents in isolated rat myelinated nreve fibres
180. Demyelinative conduction block produced by intraneural injection of human Guillain-Barré serum into rat sciatic nerve
181. Passive transfer studies in Guillain-Barré polyneuropathy
182. In vivo demyelinating activity of sera from patients with Guillain-Barré syndrome
183. Demyelination induced by serum from patients with Guillain-Barré syndrome
184. Antibody of patients with Guillain-Barré syndrome mediates complement dependent cytolysis of rat Schwann cells: Susceptibility to cytolysis reflects Schwann cell phenotype
185. Effects of Guillain-Barré sera containing antibodies against glycolipids in cultures of rat Schwann cells and sensory neurons
186. Anti-ganglioside antibodies can bind peripheral nerve nodes of Ranvier and activate the complement cascade without inducing acute conduction block in vitro
187. TGF beta trophic factors differentially modulate motor axon outgrowth and protection from excitotoxicity
188. A somatically mutated human antiganglioside antibody that induces experimental neuropathy in mice is encoded by the variable region heavy chain gene, V1-18
189. 1b antibodies: Alpha-latrotoxin-like effects on motor end plates
190. Neuromuscular blockade by immunoglobulin G from patients with Miller Fisher syndrome
191. 1 antibodies in rabbits
192. 1 ganglioside after immunization with lipopolysaccharides from Campylobacter jejuni
193. 1 antibodies by Campylobacter jejuni lipopolysaccharides
194. Monoclonal antibodies raised against Guillain-Barré syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations
195. Generation of high-titer, high affinity monoclonal IgG anti-ganglioside antibodies in mice lacking complex gangliosides
196. Mice lacking complex gangliosides develop Wallerian degeneration and myelination defects
197. Experimental models of peripheral neuropathies
198. Experimental allergic neuritis (EAN) as a model for the immune-mediated demyelinating neuropathies
199. Pathogenesis of Neuroimmunologic diseases
200. Experimental Campylobacter jejuni infection in the chicken: An animal model of axonal Guillain-Barré syndrome
201. 1b in Miller Fisher syndrome following different types of infection
202. T-cell activation in Guillain-Barré syndrome and in MS: Elevated serum levels of soluble IL-2 receptors
203. Lymphocytic subpopulations and suppressive cell activity in acute polyradiculoneuritis (GBS)
204. Circulating T cell subsets in Guillain-Barré syndrome
205. Quantitative analysis of endoneurial T-cells in human sural nerve biopsies
206. T lymphocyte activation antigens in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy
207. Molecular mimicry in Campylobacter jejuni lipopolysaccharides and the development of Guillain-Barré syndrome
208. CD1-restricted T-cell recognition of microbial lipoglycans
209. Pathology of the Guillain-Barré syndrome
210. HLA antigens in the Guillain-Barré syndrome
211. HLA antigens in Guillain-Barré syndrome
212. HLA and the T-cell receptor gene polymorphisms in Guillain-Barré syndrome
213. HLA-DR antigens in Mexican patients with Guillain-Barré syndrome
214. HLA typing and the Guillain-Barre syndrome
215. HLA antigens in the Landry-Guillain-Barré syndrome and chronic relapsing polyneuritis
216. Differential distribution of HLA alleles in two forms of Guillain-Barré syndrome
217. HLA alleles in patients with Guillain-Barré syndrome
218. Guillain-Barré and Miller Fisher syndromes subsequent to Campylobacter jejuni enteritis are associated with HLA-B54 and Cw1 independent of anti-ganglioside antibodies
219. Multiple N-acetylneuraminic acid synthase (neuB) genes in Campylobacter jejuni: Identification and characterization of the gene involved in sialylation of lipo-oligosaccharide
220. Biosynthesis of ganglioside mimics in Campylobacter jejuni OH4384